| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
|
| | PD 134922 Basic information |
| Product Name: | PD 134922 | | Synonyms: | PD 134922;L-Norvalinamide, N-(4-morpholinylsulfonyl)-L-phenylalanyl-N-[4-[(butylamino)carbonyl]-1-(cyclohexylmethyl)-2-hydroxy-5-methylhexyl]-4,5-didehydro-, [1S-(1R*,2R*,4R*)]- (9CI) | | CAS: | 150351-30-7 | | MF: | C37H61N5O7S | | MW: | 719.98 | | EINECS: | | | Product Categories: | | | Mol File: | 150351-30-7.mol |  |
| | PD 134922 Chemical Properties |
| density | 1.19±0.1 g/cm3(Predicted) | | pka | 10.97±0.20(Predicted) |
| | PD 134922 Usage And Synthesis |
| Description | PD 134922 is a novel HIV-1 protease inhibitors identified by rational selection.The human immunodeficiency virus (HIV-1), associated with the AIDS (acquired immunodeficiency syndrome) epidemic, encodes an aspartyl protease that is essential for polyprotein processing in the virus (Navia et al., 1989). It has been demonstrated that inactivation of the protease either catalytically or by an inhibitor prevents infectious virion formation (Kohl et al., 1988; Darke et al., 1989). The acquired knowledge of key molecular interactions occurring between inhibitors and aspartyl proteases, as well as the structural similarities between HIV-1 protease and human renin was used to rationally select candidates for HIV-1 screening from the pool of analogs designed as renin inhibitors. A minimal number of chosen compounds were tested in an HIV-1 protease assay system. Two structurally novel peptides emerged as potent enzymatic protease inhibitors. | | Uses | PD 134922 is a potent renin and HIV-1 protease inhibitor with an IC50 of 15 nM against HIV-1 protease[1]. | | References | [1] Humblet CC, et al. Characterization of two structurally novel HIV-1 protease inhibitors identified by rational selection. Antiviral Res. 1993 May;21(1):73-84. DOI:10.1016/0166-3542(93)90068-t |
| | PD 134922 Preparation Products And Raw materials |
|